Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 1,974 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Normal Pregnancy Clear all

Conditions: Paraganglioma, Gastrointestinal Stromal Tumors, Carcinoma, Renal Cell, Renal Neoplasms, Pheochromocytoma
Interventions: SGI-110 (guadecitabine); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 99 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cancer
Interventions: SQ3370; Drug
Lead sponsor: Shasqi, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Duarte, California • Palo Alto, California • Santa Monica, California + 4 more

Conditions: Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer, Ovarian Cancer, Breast Cancer, Bladder Cancer
Interventions: Questioners, STAR website; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Ovarian Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions: carboplatin, cisplatin, floxuridine; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: New York, New York

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions: arsenic trioxide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 40 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors
Interventions: OSI-906; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Fatigue, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: yoga therapy; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Turner Syndrome, Post-menarcheal Adolescents, Ovarian Disfunction, Galactosemia, Variations in Sex Characteristics, Differences in Sex Development
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 35 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma, Vaginal Cancer, Vulvar Cancer
Interventions: topotecan hydrochloride, pharmacological study; Drug · Other
Lead sponsor: Steven Waggoner, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Kidney Cancer, Leukemia, Lymphoma, Neurotoxicity, Peripheral Neuropathy, Sarcoma
Interventions: glutamic acid, placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 3 Years to 20 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: Fort Myers, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 3 more

Conditions: Pneumonia, Urinary Tract Infections, Soft Tissue Infections, Gastroenteritis
Interventions: As-needed follow up, Automatic follow-up; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: Up to 18 Years
Enrollment: 2,674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 14
States / cities: Phoenix, Arizona • Mountain View, California • Palo Alto, California + 10 more

Conditions: Breast Cancer, Prostate Cancer, Melanoma (Skin), Endometrial Cancer, Gallbladder Cancer, Rectal Cancer, Kidney Cancer, Bladder Cancer
Interventions: Written Weight Loss Material, Weight Loss App, Behavioral Lifestyle Weight Loss Intervention (Coaching); Behavioral
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neuroblastoma, Central Nervous System Tumors, Lymphomas, Wilms Tumor
Interventions: Stem Cell Transplantation, Busulfan, Melphalan; Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 25 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Breast Cancer
Interventions: Clinical outcomes; Other
Lead sponsor: Jules Bordet Institute; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 4,732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 7
States / cities: New Haven, Connecticut • Boston, Massachusetts • Lansing, Michigan + 4 more

Conditions: Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Glioblastoma, Prostate Cancer, Gynecologic Cancer, Colorectal Cancer, Sarcoma, Kidney Cancer, Bladder Cancer, Lymphoma, Leukemia, Head and Neck Cancer, Pancreas Cancer, Multiple Myeloma, Anxiety, Social Isolation, Stress, Loneliness, Melanoma, Uterine Cancer
Interventions: Elly Mobile Phone Application; Behavioral
Lead sponsor: Gillian Gresham; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions: filgrastim, recombinant interleukin-11; Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alport Syndrome
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 0 Years to 99 Years
Enrollment: 655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma
Interventions: filgrastim, allogeneic bone marrow transplantation; Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Nashville, Tennessee • Seattle, Washington

Conditions: Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer(NSCLC), Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Tisotumab Vedotin (HuMax-TF-ADC); Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 8
States / cities: Orange, California • New Haven, Connecticut • Miami, Florida + 5 more

Conditions: Advanced Solid Tumor
Interventions: XL309, Olaparib; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Jacksonville, Florida • Orlando, Florida • Tampa, Florida + 10 more

Conditions: Breast Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Renal Cell Cancer
Interventions: Not listed
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 50
States / cities: Many Locations, Alabama • Many Locations, Alaska • Many Locations, Arizona + 47 more

Conditions: Breast Cancer
Interventions: Video and Booklet, Factsheet; Behavioral
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
Interventions: ALXN2050, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 10
States / cities: Huntsville, Alabama • Loma Linda, California • Northridge, California + 7 more

Conditions: Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer
Interventions: Enoxaparin; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Danvers, Massachusetts

Search by objective public record fields.

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

Internet-based System for Cancer Patients to Self-report Toxicity

Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer

Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors

Study of Intermittent OSI-906 Dosing

Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer

Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy

Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery

Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer

Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial

Behavioral Weight Loss Program for Cancer Survivors in Maryland

Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas

Safety of Pregnancy in BRCA Mutated Breast Cancer Patients

Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

Alport Syndrome Treatments and Outcomes Registry

Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous Disease

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Genetic Counseling for Breast Cancer Survivors (GC for BC)

Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles